Neutral
●
GlobeNewsWire
●
6 months ago
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 13 newly-hired employees options to purchase an aggregate of 679,900 shares of Akebia's common stock on March 31, 2026. The options were granted as an inducement material to each employee en...